Patent application number | Description | Published |
20090018295 | POLYMERS FOR PREVENTING OR REDUCING ALUMINOSILICATE SCALE IN A BAYER PROCESS - Materials and a process are provided whereby polymers with the pendant group or end group containing —Si(OR″) | 01-15-2009 |
20120152852 | PROCESSES FOR REMOVING HYDRAZINE FROM HYDROXYLAMINE SOLUTIONS - The present invention relates to processes for reducing or eliminating the amount of hydrazine from a hydroxylamine-free base containing hydrazine by treating said hydroxylamine-free base with a scavenger agent, and to the hydroxylamine-free base thereby obtained, as well as to its use for producing microdispersions containing a hydroxamated polymer for use as a flocculant in the Bayer process. | 06-21-2012 |
20120153209 | MICRODISPERSIONS OF HYDROXAMATED POLYMERS AND METHODS OF MAKING AND USING THEM - Methods of producing microdispersions containing hydroxamated polymers by reacting water-in-oil microdispersions having vinyl polymers containing one or more pendant functional groups that react with hydroxylamine, with a hydroxylamine-free base substantially free of inorganic salt and containing less than 500 ppm hydrazine are disclosed herein, along with the microdispersions thereby obtained. | 06-21-2012 |
20130092603 | Collector Compositions and Methods of Using the Same - Formulations for value mineral collector compositions composed of at least one first collector selected from an organic ammonium salt of an organic sulfur-containing acid; and at least one second collector selected from neutral collectors and/or organic ammonium salts of an organic sulfur-containing acids, such that the second collector is different from said first collector, are provided herein, along with methods for making and using same. | 04-18-2013 |
20130092604 | Froth Flotation Processes - Froth flotation processes that include adding a beneficiating amount of a value mineral collector composed of an organic ammonium salt of a sulfur-containing acid to at least one stage of a froth flotation process to recover value minerals from mineral ore bodies are disclosed herein. | 04-18-2013 |
20130092605 | Froth Flotation Processes - Froth flotation processes that include adding a beneficiating amount of a value mineral collector composed of an organic ammonium salt of a sulfur-containing acid to at least one stage of a froth flotation process to recover value minerals from mineral ore bodies are disclosed herein. | 04-18-2013 |
Patent application number | Description | Published |
20140276219 | Placental and Cord Blood Collection Device with Safety - A novel blood collection device is described to secure a needle in place in a placenta or umbilical cord to prevent needle stick before, during, and after cord blood collection procedure. | 09-18-2014 |
20140308165 | Biological Fluid Collection Device and Biological Fluid Separation and Testing System - A biological fluid collection device that is adapted to receive a multi-component blood sample having a cellular portion and a plasma portion is disclosed. After collecting the blood sample, the biological fluid collection device is able to separate the plasma portion from the cellular portion. After separation, the biological fluid collection device is able to transfer the plasma portion of the blood sample to a point-of-care testing device. The biological fluid collection device also provides a closed sampling and transfer system that reduces the exposure of a blood sample and provides fast mixing of a blood sample with an anticoagulant. The biological fluid collection device is engageable with a testing device for closed transfer of a portion of the plasma portion from the biological fluid collection device to the testing device. The testing device is adapted to receive the plasma portion to analyze the blood sample and obtain test results. | 10-16-2014 |
20140308167 | Biological Fluid Sampling Transfer Device and Biological Fluid Separation and Testing System - A biological fluid sampling transfer device that is adapted to receive and separate a multi-component blood sample is disclosed. After separation, the biological fluid sampling transfer device is able to transfer a plasma portion of the blood sample to a point-of-care testing device. The biological fluid sampling transfer device of the present disclosure also provides a closed sampling and transfer system that reduces the exposure of a blood sample and provides fast mixing of a blood sample with an anticoagulant. The biological fluid sampling transfer device is engageable with a blood testing device for closed transfer of a portion of the plasma portion from the biological fluid sampling transfer device to the blood testing device. The blood testing device is adapted to receive the plasma portion to analyze the blood sample and obtain test results. | 10-16-2014 |
20140309555 | Biological Fluid Collection Device and Biological Fluid Separation and Testing System - A biological fluid collection device that is adapted to receive a blood sample having a cellular portion and a plasma portion is disclosed. After collecting the blood sample, the biological fluid collection device is able to transfer the blood sample to a point-of-care testing device or a biological fluid separation and testing device. After transferring the blood sample, the biological fluid separation and testing device is able to separate the plasma portion from the cellular portion and analyze the blood sample and obtain test results. | 10-16-2014 |
20140309556 | Biological Fluid Collection Device and Biological Fluid Collection and Testing System - A blood collection device adapted to receive a multi-component blood sample is disclosed. After collecting the blood sample, the blood collection device separates a plasma portion from a cellular portion. After separation, the blood collection device is able to transfer the plasma portion of the blood sample to a point-of-care testing device. The blood collection device of the present disclosure also provides a closed collection and transfer system that reduces the exposure of a blood sample and provides fast mixing of a blood sample with a sample stabilizer. The blood collection device is engageable with a blood testing device for closed transfer of a portion of the plasma portion from the blood collection device to the blood testing device. The blood testing device is adapted to receive the plasma portion to analyze the blood sample and obtain test results. | 10-16-2014 |
20140309557 | Biological Fluid Sampling Transfer Device and Biological Fluid Separation and Testing System - A blood separation and testing system for a blood sample is disclosed. The blood separation and testing system includes a blood sampling transfer device adapted to receive a blood sample, a blood separation device, and a blood testing device. The blood separation device is adapted to receive a portion of the blood sampling transfer device such that with the blood sampling transfer device received within the blood separation device and a rotational force applied to the blood sampling transfer device, a plasma portion of the blood sample is separated from a cellular portion of the blood sample. The blood testing device is adapted to receive a portion of the blood sampling transfer device to analyze the plasma portion of the blood sample and obtain test results. | 10-16-2014 |
Patent application number | Description | Published |
20130053580 | ORGANOPHOSPHORUS COMPOUNDS, CATALYTIC SYSTEMS COMPRISING SAID COMPOUNDS AND METHOD OF HYDROCYANATION USING SAID CATALYTIC SYSTEMS - The present invention relates to organophosphorus compounds belonging to the phosphinite-phosphite family, catalytic systems comprising a metallic element forming a complex with said phosphinite-phosphite compounds and methods of hydrocyanation employed in the presence of said catalytic systems. | 02-28-2013 |
20130266788 | PROCESS FOR PREPARING FOAMED POLYMER - The invention pertains to a process for producing a glycerol tri-carboxylic acid polyester foam which comprises the steps of combining glycerol and a tri-carboxylic acid in the liquid phase to provide a reaction mixture, and keeping the reaction mixture at a temperature of between 80° C. and 130+ C. from the start of the reaction until a conversion of at least 90% is obtained. | 10-10-2013 |
20140087936 | CORE-SHELL PARTICLES WITH CATALYTIC ACTIVITY - The present invention pertains to novel core-shell particles comprising a core of iron oxide and a shell of cobalt oxide, characterized in that they are spherical with a number average diameter, as measured by TEM, of between 1 and 20 nm. This invention is also directed to their uses in the manufacture of a catalyst, and to the method for preparing these particles, by precipitating cobalt oxide onto magnetite or hematite particles which are themselves precipitated from Fe(III) and optionally Fe(II) salts. | 03-27-2014 |
20150306573 | CORE-SHELL PARTICLES WITH CATALYTIC ACTIVITY - The present invention pertains to novel core-shell particles comprising a core of alumina and a shell of cobalt oxide, characterized in that they are spherical with a number average diameter, as measured by TEM, of between 10 and 30 nm. This invention also pertains to the method for preparing these core-shell particles and to their uses in the manufacture of a catalyst. | 10-29-2015 |
Patent application number | Description | Published |
20090269774 | EVALUATION OF EOSINOPHILIC ESOPHAGITIS - A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome. | 10-29-2009 |
20110301046 | Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis - The present invention concerns methods useful in diagnosing, identifying and monitoring the progression of eosinophilic esophagitis through measurements of gene products. | 12-08-2011 |
20120283117 | DETERMINATION OF EOSINOPHILIC ESOPHAGITIS - Eosinophilic esophagitis (EE), an emerging disorder with poorly understood pathogenesis, was examined. Esophageal tissue was analyzed by a genome wide microarray expression analysis. EE patients had a transcript signature involving 1% of the genome that was conserved across gender, age, and atopic status, and was distinct from that associated with chronic esophagitis (CE). The eosinophil specific chemokine eotaxin-3 was the top induced gene compared with normal controls. Levels C of eotaxin-3 mRNA and protein correlated with disease severity. A single nucleotide polymorphism in the human eotaxin-3 gene conferred susceptibility to disease. Mice deficient in the eotaxin-3 receptor (CCR-3) were protected from experimental EE. Eotaxin-3 was identified as a specific effector molecule, biomarker, and genetic risk factor for EE, and distinguished EE from CE. | 11-08-2012 |
20130177575 | NOVEL THERAPEUTIC TARGET AND DIAGNOSTIC MARKER FOR ASTHMA AND RELATED CONDITIONS - CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression. | 07-11-2013 |
20130324435 | ESOPHAGEAL CYTOKINE EXPRESSION PROFILES IN EOSINOPHILIC ESOPHAGITIS - Methods and compositions disclosed herein generally relate to methods of providing or enhancing a diagnosis of eosinophilic esophagitis (EE). In particular, the invention relates to obtaining a sample from a patient having at least one indication of EE, then quantifying from the sample an amount of one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor, wherein an altered level of the cytokine or mRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor. | 12-05-2013 |
20140286896 | MOLECULAR DIAGNOSTIC PANEL OF EOSINOPHILIC GASTROINTESTINAL DISORDERS - Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the EG status of the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EG in a subject. Embodiments of the invention are also directed to use of CDH26 as a marker for EG, eosinophilic esophagitis, or allergic inflammatory conditions. Embodiments of the invention also relate to the use of anti-CDH26-based therapeutics to treat allergic inflammatory conditions. | 09-25-2014 |
20150038552 | ESOPHAGEAL MICRORNA EXPRESSION PROFILES IN EOSINOPHILIC ESOPHAGITIS - Methods and compositions disclosed herein generally relate to methods of treating eosinophilic esophagitis (EE) and eosinophilic disorders by providing or enhancing a diagnosis of EE and eosinophilic disorders. In particular, the invention relates to obtaining a sample from a patient, then quantifying from the sample an amount of one or more microRNAs (miRNAs) associated with EE, wherein an altered level of the miRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step, and an appropriate treatment can be administered to the patient. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more miRNAs associated with EE, as well as treatments developed to up-regulate or down-regulate one or more miRNAs and/or their downstream pathways relevant to EE or asthma. The invention further relates to the use of IGF1 and IGF1R inhibitors for the treatment of EE and eosinophilic disorders. | 02-05-2015 |
20150045334 | DIAGNOSTIC METHODS OF EOSINOPHILIC ESOPHAGITIS - Embodiments of the invention are directed to methods of diagnosing eosinophilic esophagitis (EoE), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EoE, analyzing to obtain relatedness information relative to an EoE cohort and making a determination as to the EoE status of the subject, wherein an analysis indicating grouping with an EoE cohort or a quantitative score similar to that of an EoE cohort are indicative of EoE in the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EoE in a subject. | 02-12-2015 |
20150098952 | NOVEL THERAPEUTIC TARGET AND DIAGNOSTIC MARKER FOR ASTHMA AND RELATED CONDITIONS - CD48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. CD48 is thus presented as a target molecule in the treatment of said conditions. In addition, diagnostic methods, and a kit for the diagnosis of allergic inflammatory conditions are described, based on the detection of CD48 expression. | 04-09-2015 |
20160129012 | COMPOSITIONS AND METHODS FOR TREATING ALLERGIC INFLAMMATION THROUGH INHIBITION OF NTRK1 - The invention provides methods of treating allergic inflammatory conditions using an anti-neurotrophin tyrosine kinase receptor 1 (NTRK1)-based therapeutic agent, and related compositions and methods. | 05-12-2016 |